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 A simple method is presented for forming thread-like fi bers from highly vis-
cous dextran solutions. Based on the cohesive and adhesive forces between a 
dextran solution and the substrate to which it is applied, multiple fi bers of ap-
proximately 10 µm in diameter can be elongated simultaneously. These fi bers 
can be woven into multiple layers to produce fabrics of varying fi ber orienta-
tions and mechanical properties. Various bioactive agents can be incorpo-
rated into the dextran solution prior to fi ber formation, including hemostatic 
and antibiotic agents. Fabrics containing thrombin are capable of coagulat-
ing human platelet poor plasma in vitro. Fabrics containing antibiotics are 
capable of suppressing bacterial growth in a disk diffusion assay. These data 
suggest that this new material composed entirely of dextran has promise as a 
drug delivery component in wound dressings. 
the form of sponge-type constructs. For 
example, chitosan and collagen sponges 
have been used as topically applied wound 
dressings for burns and abrasions to pro-
mote wound healing. [ 10,15 ] These materials 
also provide the ability to release factors 
that can promote bioresorption and tissue 
remodeling at the wound site. 
 In addition to their applications as 
wound dressing materials, polymer-based 
fi ber materials, which can be fabricated 
through electrospinning, have found 
applications as fi ltration matrices, coating 
fi lms, drug release scaffolds, and tissue 
engineering materials. [ 16,17 ] Electrospin-
ning can be used to produce biopolymer 
matrices composed of fi bers ranging in 
diameter from tens of nanometers to several micrometers that 
can potentially carry drugs or promote remodeling of injured 
tissues by serving as a matrix for cell interaction. [ 7,16,18–21 ] 
Importantly, as mentioned above, these electrospun materials 
can be tuned to provide optimal fi ber sizes, pore sizes, and fi ber 
orientations for specifi c applications. [ 16 ] Moreover, the high sur-
face area of the fi ber architecture can enhance drug release and 
bioresorption. [ 22 ] 
 There are, however, several drawbacks to electrospun fab-
rics, including the time and equipment required for their fab-
rication, which have limited their widespread adoption by the 
scientifi c community. Electrospinning also at times suffers 
from fabrication defects in the form of beading [ 23 ] and pores [ 24 ] 
within the polymer fi bers. Moreover, the types of polymers that 
can be electrospun are sometimes limited because the nozzles 
used for liquid jetting can become clogged by viscous polymer 
solutions. To overcome limitations in beading and to adjust the 
viscosity to control the range of fi ber diameters, fi ller mate-
rials are typically incorporated into the polymer solutions prior 
to electrospinning. [ 25,26 ] However, this presents an additional 
problem in that the fi ller material may interfere with down-
stream biomedical applications, either by remaining in trace 
amounts in the fi nal material or by interfering with the bioac-
tivity of the drug or protein components incorporated into the 
polymeric material. 
 Here, we present a simple and rapid method for forming 
microscale diameter polymer fi bers without the use of elec-
trospinning. This method can be used to form dextran fabrics 
capable of carrying and delivering drugs such as hemostatic 
 1.  Introduction 
 Topical, transdermal, and oral treatment systems often involve 
the release of bioactive compounds from a delivery matrix. [ 1–5 ] 
In the case of topical or transdermal treatment systems, the 
delivery matrix often takes the form of a thin, planar mate-
rial that is brought into conformal contact with the skin or the 
mucosal tissue. These systems are often fabricated using elec-
trospun polymeric scaffolds that allow the rate of drug release 
to be controlled by tuning the pore size and interconnectivity of 
the scaffold, among other factors. [ 3,6 ] Similar types of scaffolds 
have been applied as wound dressings. [ 3,7,8 ] To facilitate healing 
and control drug release rates, the latest scaffolds are often bio-
degradable with tunable biodegradation rates. 
 There are also several other types of topical wound dressings 
available for the treatment of open wounds such as lacerations, 
abrasions, and burns. [ 1,5,9 ] Many of these wound dressings 
incorporate biopolymers, such as collagen and fi brin, to pro-
mote wound healing or reduce scarring. [ 8,10–15 ] For example, col-
lagen- and fi brin-based materials have been applied to wounds 
by implantation or injection in combination with other surgical 
procedures. It is also possible to apply biopolymer scaffolds in 
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agents and antibiotics. This method takes advantage of the 
adhesive/cohesive forces of highly viscous dextran solutions 
stretched between two substrates, resulting in the formation 
of fi bers that rapidly dry in air due to their high surface area 
without the use of any solvents other than water. The mate-
rial properties of these fabrics are characterized by mechanical 
failure testing and scanning electron microscopy (SEM). We 
demonstrate a medical application for these dextran fabrics by 
delivering thrombin and antibiotics by way of rapid dissolution 
of the dried fabrics upon contact with moist surfaces. The dex-
tran fabrics are capable of clotting human platelet poor plasma 
and preventing bacterial growth on agar plates. Since medical 
grade (FDA approved) dextran is already commercially available 
and lends itself to medical applications, these proof-of-concept 
experiments may lead to further applications of dextran fabrics 
as topical or oral drug delivery systems or as advanced wound 
healing/remodeling materials. 
 2.  Results 
 2.1.  Dextran Fabric Generation and Characterization 
 The 500 000 g mol −1 dextran used in this study was soluble 
in water up to a concentration of approximately 60 wt% 
(Figure S1, Supporting Information). At 70 wt% the dextran 
formed an opaque nearly-solid material. At concentrations 
above 70 wt% there were signifi cant quantities of dry dextran 
that were not incorporated into the mixture. Concentrations of 
dextran between 40 and 60 wt% were capable of forming fi bers 
by tension between two substrates. As strands of dextran solu-
tion extended from the dextran source, evaporative water loss 
occurred, resulting in dry fi bers with diameters of approximately 
10 µm, which varied depending on the concentration of the dex-
tran source solution and the strain rate of fi ber  extension. It was 
possible to form multiple fi bers simultaneously by increasing 
the cross-sectional area of the dextran volume under tension 
between two relatively large, fl at substrates, such as wooden 
tongue depressors, that were brought into conformal contact 
before extending them apart with a swift motion. 
 When the dextran solution is in contact with the substrates 
(in this case the wooden tongue depressors), many of the dex-
tran chains will be coiled and entangled among each other. 
The polymer solution elongates from a number of contact 
points between the two substrates. As the tongue depressors 
are separated, tensile stress is imposed on the dextran chains 
as the highly viscous dextran solution dries, likely resulting in 
uncoiling and elongation of the dextran chains. Adhesive forces 
keep the dextran solution attached to each wooden tongue 
depressor, while cohesive forces between the dextran chains pre-
vent the strands of dextran solution from breaking ( Figure  1 A). 
The strands of dextran solution are able to withstand signifi -
cant elongation forces (generated manually) without breaking 
because of the cohesive forces in the solution and the hydrogen 
bonding between the chains and branches of the dextran mol-
ecules (Figure  1 B). [ 27,28 ] This combination of the adhesive and 
cohesive forces in the system allows strands of dextran solution 
to be formed that dry rapidly in air to form dextran fi bers. 
 A total of nine types of fabrics were generated by this fi ber 
extension process, including fabrics of three different thick-
nesses (generated by 50, 100, or 200 layered fi ber extensions) 
with three different orientations (unidirectional, bidirectional, 
or multidirectional by rotating the fabric between extensions). 
Macroscopic and SEM images of the fabrics are shown in 
Figure  1 C–H. These fabrics were submitted to mechanical uni-
axial tensile testing with the direction of strain aligned with, 
perpendicular to or at a 45° to the main orientation of the 
dextran fi bers in the fabrics ( Figure  2 A–C). The toughness of 
the fabric decreased with the number of fi ber layers for all of 
the fabric types, as indicated by the force displacement curves 
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 Figure 1.  Formation of dextran fi bers by elongation and drying of liquid strings of dextran solution. A) Highly viscous solutions of dextran form liquid 
strings between two substrates due to adhesive forces ( F ad ) between the dextran solution and the substrate and cohesive forces ( F co ) within the dextran 
solution as the solution is pressed between two substrates that are then moved apart to generate tension. B) On the molecular level, the cohesive 
forces are derived from entanglement of the dextran polymer chains and interchain hydrogen bonding. C–E) Multiple fi bers can be elongated simulta-
neously to produced multilayered fabrics with the fi bers oriented in one direction (180° symmetry; C), two directions (90° symmetry; D) and multiple 
directions (45° symmetry; E). Scale bars are 10 mm. F–H) SEM images of the fabrics with fi bers oriented in one direction (F), two directions (G), and 
multiple directions (H). Scale bars are 50 µm.
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(Figure  2 D–F). Fabrics with a greater number of fi bers aligned 
with the direction of strain were able to endure greater loads 
for the same number of dextran fi ber layers. As expected, the 
unidirectional (180° symmetry) fabrics were able to withstand 
strain only when the direction of strain was aligned with the 
fi bers (Figure  2 G). This fabric type also had the greatest ulti-
mate tensile strength in a single direction. The mechanical 
properties of the bidirectional (90° symmetry) fabrics were 
the same in the horizontal and vertical strain directions, but 
were slightly weaker when strain was applied diagonal to the 
fi ber orientation (Figure  2 H). The mechanical properties of 
the multidirectional (45° symmetry) fabrics were the same for 
each strain direction (Figure  2 I). These tendencies are apparent 
from the stress strain curves (Figure  2 G–I) and ultimate tensile 
strength graphs (Figure  2 J–L). The mechanical testing indicates 
that the fabrics have suffi cient strength for manufacturing and 
handling during medical procedures. Moreover, the fi ber orien-
tation can be used to design fabrics that are strong in one direc-
tion, but can be easily torn in another direction. 
 2.1.  Drug Delivery using Dextran Fabrics 
 We tested the fabrics as vehicles for drug delivery by deliv-
ering thrombin and antibiotics in vitro. SEM analysis revealed 
that there was no difference in fi ber diameter when thrombin 
was incorporated into the fi bers (Figure S2, Supporting Infor-
mation). We used a microplate assay based on absorbance at 
405 nm to examine the kinetics of thrombin-induced plasma 
coagulation. When thrombin solution was added directly to the 
plasma, we observed a dose-dependent increase in the absorp-
tion at 405 nm due to polymerization of the fi brinogen in the 
plasma into fi brin (Figure S3, Supporting Information). Based 
on this calibration data, we selected a thrombin concentration 
of 31 U mL −1 for subsequent experiments. For comparison of 
the microplate absorbance data between the four thrombin con-
ditions, 1) plasma -thrombin, 2) plasma +thrombin, 3) plasma 
+dextran fabric only, and 4) plasma +dextran fabric containing 
thrombin, the values were normalized. 
 The plasma only condition displayed a low baseline that fl uc-
tuated around 0.4, whereas when the thrombin solution was 
added, a rapid increase to maximum was observed over the 
course of approximately 10 min ( Figure  3 A). When the dex-
tran fabrics were applied to the plasma, we observed a sharp 
increase in the absorbance due to the fabric alone, which 
gradually decreased over the course of the data collection 
period (Figure  3 B, black symbols). This was likely due to the 
colloidal dissolution of the dextran fabric interfering with the 
optical measurements. When thrombin-containing fabrics were 
applied to the plasma, the absorbance rapidly increased in the 
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 Figure 2.  Mechanical testing of the dextran fabrics. A–C) Schematic representations of the fi ber orientations with the relative directions of strain 
indicated by the colored arrows for the unidirectional fabrics (180° symmetry; A), bidirectional fabrics (90° symmetry; B) and multidirectional fabrics 
(45° symmetry; C). D–F) Force-displacement data in the vertical direction of strain for the unidirectional fabrics (D), bidirectional fabrics (E), and 
multidirectional fabrics (F) for 50, 100, and 200 layers of fi bers. G–I) Stress-strain data for all four directions of strain for the unidirectional (G), bidi-
rectional (H), and multidirectional (I) fabrics for 200 layers of fi bers. J–L) The corresponding ultimate tensile strength data obtained from plots (G–I).
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fi rst 10 min, after which time the absorbance stabilized, similar 
to when thrombin solution was added directly to the plasma 
(Figure  3 B, green symbols). 
 These data were corroborated by microscopic observation 
of fi brin polymerization (Figure  3 C). The plasma to which the 
thrombin solution was added directly displayed microscopic 
structures that we ascribed to fi brin polymerization. These 
structures were absent when only water was added to the 
plasma. We observed incomplete colloidal dispersion of the 
dextran (without thrombin) after it was added to the plasma. 
The fabric alone was not capable of coagulating the plasma 
based on our observation of the absence of plasma gelation. 
Finally, when thrombin was delivered using the fabric as a 
vehicle, microscopic structures similar to those observed for 
thrombin added in solution were observed. We confi rmed 
plasma coagulation after imaging by manually manipulating 
the fabric-treated clots. We also tested the ability to deliver anti-
biotics using a disk diffusion assay with BL21  Escherichia coli 
( Figure  4 ). The dextran fabrics dissolved immediately upon con-
tact with the agar plate. The fabrics alone were not capable of 
suppressing bacterial growth. However, we observed increased 
areas of clearance with increasing concentrations of antibacte-
rial agents in the fabrics. 
 3.  Discussion 
 Examples of advanced wound dressing systems range from 
fi brin and collagen glues to biomaterial sponges and elec-
trospun polymer composites, all of which can be designed to 
stop bleeding, promote tissue remodeling, and deliver drugs 
or factors to aid in tissue repair or prevent infection. There are 
several examples of dextran-based materials fabricated by elec-
trospinning. [ 7,18–20,29–32 ] These materials are typically polymer 
blends, for example, dextran/PLGA, that range in fi ber diam-
eter from hundreds of nanometers to tens of micrometers. [ 7,29 ] 
Electrospun dextran materials are typically cross-linked to limit 
their solubility, although most are bioresorbable. In this report, 
we produced dextran fabrics that were qualitatively similar to 
the electrospun dextran mats reported in previous studies. 
However, unlike the previous examples of cross-linked dex-
tran fi bers, our fi bers were not cross-linked, allowing them to 
rapidly dissolve upon contact with moist surfaces. Although 
our fabric materials do not currently utilize polymer blends or 
cross-linking methods to stabilize the fi bers, these approaches 
could be implemented to provide additional functionality. 
 It is worth noting that almost all of the previous studies on 
dextran fi ber mats/fabrics used electrospinning as a fabrication 
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 Figure 3.  Dextran fabrics containing thrombin are capable of clotting plasma in vitro . A) Normalized absorbance at 405 nm for control plasma (No 
Fabric/0 U mL −1 Thrombin; black symbols) and plasma with thrombin added in solution (No Fabric/ 31 U mL −1 Thrombin; green symbols). The absorb-
ance at 405 nm increases to its maximum by ≈500 s with thrombin. B) Normalized absorbance at 405 nm for plasma with the dextran fabric alone 
(black symbols) and with the dextran fabric containing thrombin (green symbols). The fabric alone interferes with the absorbance measurement at 
early time points in the assay. The absorbance at 405 nm increases to its maximum by ≈500 s with the addition of thrombin, similar to when thrombin 
is added to plasma without the fabric. C) Optical microscopy with a linear polarizing fi lter revealed that the artifact present in the absorbance data was 
likely caused by incomplete colloidal dispersion of the dextran fabric in the plasma (bottom left). The plasma coagulated with the fabric containing 
thrombin displayed microscopic structures that were qualitatively similar to those observed when the plasma was coagulated with thrombin alone. 
Scale bar is 50 µm.
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method. Electrospinning has its roots in more traditional fi ber 
spinning techniques, [ 33 ] such as dry spinning, [ 34,35 ] which is 
similar to our method, wet spinning, [ 36 ] and other industrial 
spinning methods including extrusion spinning and melt spin-
ning. Electrospinning offers the advantage that it can be used to 
generate ultrafi ne nanoscale fi bers with directed orientations. 
These fi bers can be collected on a variety of substrates of var-
ious sizes and geometries. [ 37 ] However, since electrospinning 
requires a substrate, electrospun materials are typically used as 
thin coatings. Although our fi bers are larger in diameter than 
those typically achieved by electrospinning, we are also able to 
orient the fi bers in multiple direction, while offering the advan-
tage of having a free standing fabric material, rather than a 
fabric-like mat coated on a larger solid substrate. 
 In many cases, cross-linked electrospun mats are used for 
drug delivery, but the drugs are typically added after spinning 
to avoid exposure to solvent, or harsh drying or cross-linking 
conditions. Our method for generating fabrics does not involve 
the use of any organic solvents, allowing sensitive drugs or 
proteins to be directly incorporated into the fi bers. In contrast, 
if drugs or proteins are directly incorporated into electrospun 
polymers, they may become damaged or denatured by exposure 
to organic solvents or other factors that are commonly used to 
promote more consistent jetting from the electrospinning head 
and reduce the fi ber diameter. Since dextran is also used as an 
excipient and a stabilizer for drugs and proteins, it may also 
help to maintain the activity of the reagents incorporated in the 
fi bers. 
 As described above, materials similar to our dextran fabrics 
have found a variety of biomedical application ranging from 
drug delivery to wound dressings. Similar materials have been 
tested for BSA and lysozyme delivery in vitro, [ 30 ] VEGF delivery 
to HUVECs in vitro [ 18 ] and antibacterial agent delivery. [ 7 ] These 
materials have also found applications as cell scaffolds for 
fi broblasts and other cell types. [ 19–21 ] Their high surface areas, 
ability to release active biomolecules, biocompatibility, and 
ability to serve as a matrix for cells makes them ideal materials 
for wound dressings. In our study, we used fabrics entirely 
composed of non-cross-linked dextran to deliver hemostatic 
agents and antibiotics. Our fabrics dissolved immediately 
upon contact with moist surfaces, releasing their bioactive 
constituents. This offers the possibility of immediate release 
as a component of a multicomponent wound dressing with 
other cross-linked or slowly degrading components. It might 
also be possible to use this fi ber forming method to form fab-
rics from other polymers with biomedical applications (e.g., 
carbohydrate polymers such as alginate, chitosan, or cellulose 
derivatives). 
 One caveat of this system is that dextran is known to inter-
fere with coagulation. [ 38–41 ] This effect seems to be mediated 
through hemodilution along with non-specifi c interference 
with the coagulation system. These effects are more pro-
nounced with lower molecular weight dextrans, especially 
when applied in large volumes to the blood, and may result 
from interference caused by colloidal interactions. In our 
system, we observed interference of dextran with the coagula-
tion assay. We hypothesized that this was partially caused by 
incomplete dissolution of the dextran in the plasma. This was 
confi rmed by the polarized microscopy images that showed 
dextran aggregates in the plasma. Interestingly, the presence of 
high molecular weight (500 000 g mol −1 ) dextran did not seem 
to interfere with thrombin-catalyzed fi brin polymerization, 
as indicated by the absorbance data, the morphology of the 
clotted plasma and our observation that gel-like clots formed 
after thrombin delivery by way of the dextran fabrics.  However, 
more detailed testing beyond the scope of this  proof-of-concept 
study will be required to conclusively demonstrate a lack of 
interference with clotting or wound healing when thrombin is 
applied with dextran. Similar colloidal/insolubility effects were 
not observed in buffers, water, or on the surface of the agar 
plates used in the disk diffusion assay for antibiotic delivery 
testing. 
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 Figure 4.  Antibiotics incorporated into dextran fabrics suppress bacterial growth in a disk diffusion assay. Anti–anti (penicillin, streptomycin and 
fungizone) was incorporated into the 50% dextran solution prior to fi ber/fabric formation. A) Biopsy punches (6 mm in diameter containing different 
concentrations of anti–anti) were placed on LB agar plates freshly seeded with  E. coli BL21 cells. The fabrics dissolve upon contact with the moist agar 
surface, releasing the antibiotics. The red dashed circles indicate the approximate coverage area of the biopsy punches. B) Quantifi cation of the disk 
diffusion assay for  n = 3 agar plates. The actual quantities of anti–anti delivered to the surface of the plates were 1× (0.06 U penicillin, 0.06 mg strep-
tomycin and 0.16 ng fungizone), 5× (0.31 U penicillin, 0.31 mg streptomycin, and 0.78 ng fungizone), and 50× (3.1 U penicillin, 3.1 mg streptomycin 
and 7.75 ng fungizone).
FU
LL
 P
A
P
ER
318 wileyonlinelibrary.com © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
 4.  Conclusions 
 We developed a new fabric material composed of microscale 
dextran fi bers that can be easily fabricated without complex 
equipment. We applied this new fabric material for delivery of 
bioactive reagents such as hemostatic drugs and antibiotics. 
We characterized the mechanical properties of fabrics with dif-
ferent fi ber layer number and orientations and demonstrated 
their ability to clot plasma and suppress bacterial growth. We 
see a direct application for this material as a component of 
wound dressings, since medical grade dextran is already com-
mercially available and FDA-approved for medical applications. 
However, in the future, it could also be possible to use blends 
of other cross-linkable polymers with dextran to generate sim-
ilar fabrics. Further studies employing circular dichroism spec-
troscopy or other analytical methods will be required to identify 
any interactions that might be present between incorporated 
drugs and the polymers used to form the fi bers. These multi-
component fabric blends could potentially be used in more 
demanding applications for sustained drug delivery or as con-
structs for promoting wound healing. 
 5.  Experimental Section 
 Dextran Formulations : Technical grade dextran (MW ≈500 000 g mol −1 ; 
Pharmacosmos, Denmark) was dissolved at varying concentrations (10, 
20, 30, 40, 50, 60, 70, 80, and 90 wt% in ddH 2 0 at room temperature 
on a rotary shaker for 24 h. The colloidal dextran solutions were then 
centrifuged to remove any air bubbles that were present in solution. 
Where applicable, the antibiotic (anti–anti from Life Technologies) or 
thrombin solutions (Equitech Bio, Kerrville, TX) were incorporated by 
gentle mixing with a pipette tip prior to fi ber formation. 
 Fabric Formation : The viscous dextran solutions were applied at a 
volume of approximately ≈750 µL to wooden tongue depressors using 
a 1 cc syringe. The tongue depressors were then separated to elongate 
the dextran strings, which dried rapidly under ambient conditions. The 
strands of dextran solution (10–20 per elongation) were extended over 
a plastic cup containing metal weights to hold it in place. The fi ber 
elongation procedure was repeated using the same tongue depressors, 
replenishing the dextran solution as needed to form fabrics of 50, 100, or 
200 layers in three different orientations, unidirectional (180° symmetry), 
bidirectional (90° symmetry), or multidirectional (45° symmetry), by 
rotating the plastic cup between layers. The fabric specimens were cut 
from the cups and stored at room temperature or at –80 °C until later 
use. 
 Mechanical Testing : The fabrics specimens were cut into testing strips 
measuring ≈5 cm in length, 1 cm in width, with varying thicknesses 
for the 200, 100, and 50 layer fabrics. For each fabric thickness and 
fi ber orientation, the test strips were cut in the directions horizontal, 
vertical, and diagonal to the primary direction of the fi bers. The test 
strips were mounted on a Test Sources Model 1000 material testing 
machine for tensile testing using a 10 lb load cell. The test strips were 
placed within the grip calipers such that the total length between the 
calipers was 3.8 cm and pulled until failure at a displacement rate of 
0.25 mm s −1 . The force–displacement data and stress–strain data were 
plotted in Sigmaplot with Sigmastat and the ultimate tensile strength 
was determined from the peak of the stress–strain curve. 
 Scanning Electron Microscopy : The fabrics were cut into 1 cm × 1 cm 
and mounted on SEM studs using conductive tape. The fabrics were 
imaged on FEI Quanta 3D SEM/FIB and Philips XL30ESEM systems 
using an accelerating voltage of 70 kV for the FEI SEM and 30 kV for the 
Philips ESEM at a pressure of 0.4 torr. The samples were imaged in their 
native state without metal coating. 
 Fibrin Clotting Assay : Fibrin clotting assays were carried out according 
to a previously published procedure with slight modifi cations. [ 42 ] 
Platelet-poor human plasma (purchased from Bioreclamation, 
Hicksville, NY) was thawed and centrifuged at 16.1 rcf for 5 min and 
then stored on ice while the microplate was prepared. Fabric punches 
were made with a 6 mm biopsy punch and weighed before they were 
used for plasma coagulation. The punches were stacked and cut as 
necessary to control the concentration of thrombin being delivered 
during the assay. This weight was 0.31 mg for most trials. The fabrics 
were then loaded in the microplate wells. Controls, such as the 
thrombin and no fabric conditions, were added to additional wells. A 
volume of 100 µL of plasma was then added simultaneously to each 
of the wells using a multichannel micropipette. The microplate was 
gently tapped for 5 s to promote mixing before starting the microplate 
reader, which was preconfi gured to measure the light absorbance 
of the samples over time. The absorbance values were normalized 
according to
 
z
x
i
i x
x x
min
max min
=
−
−   
 where  z i is the normalized absorbance at 405 nm,  x i is the sample 
absorbance value at 405 nm, and max x and min x are the maximum and 
minimum absorbance values over the course of the assay, respectively. 
The maximum absorbance value typically occurred at the last time 
point (900s) of the test with thrombin and the lowest absorbance value 
was typically observed at the earliest time point (0s) of the test with 
thrombin. 
 Optical Microscopy : Clot formation was further examined using an 
Olympus BX51 microscope equipped with a light source and a linear 
polarizer. Ten microliters of plasma was placed on a glass coverslip. 
The fabric samples containing thrombin, the fabric alone, distilled water 
(1 µL) or thrombin alone were then added to the plasma. The fi nal 
thrombin concentration was 31 U mL −1 for comparison with the clotting 
assay described above. After a 2 min incubation to allow coagulation, 
the samples were sandwiched between a second glass coverslip for 
brightfi eld imaging. 
 Agar Plate Assay : LB agar plates were prepared for a disk diffusion 
assay using BL21  E. coli cells. The  E. coli cells were seeded on the LB 
agar plates and incubated at 37 °C for 1 h. The fabrics were made in 
the same fashion as those containing thrombin, except the antibiotic 
solution was used in place of thrombin. Dextran fabrics containing 
anti–anti were made using solutions of 50×, 5×, and 1× strength anti–
anti in 50% dextran from an initial anti–anti solution of 10 000 U mL −1 
penicillin, 10 000 mg mL −1 streptomycin, and 25 µg mL −1 fungizone 
(100× concentration). Fabrics with no antibiotics were used as controls. 
The plates were then removed from incubation and 6 mm diameter 
punches of the fabrics containing the various anti–anti concentrations 
were placed on the plates. The plates were incubated for an additional 
24 h and photographed. 
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